Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy
and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care
in the treatment of newly diagnosed GBM patients. The device is an experimental, portable,
battery operated device for chronic administration of alternating electric fields (termed
TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated
electrode arrays.